Faeth Therapeutics, Inc. (FTH)
12.68
-9.37
(-42.49%)
USD |
NASDAQ |
Nov 09, 16:00
12.39
-0.29
(-2.29%)
After-Hours: 04:40
Faeth Therapeutics Enterprise Value : 159.80M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 159.80M |
| November 06, 2026 | 401.94M |
| November 05, 2026 | 346.90M |
| November 04, 2026 | 348.70M |
| November 03, 2026 | 339.92M |
| November 02, 2026 | 329.06M |
| October 30, 2026 | 315.11M |
| October 29, 2026 | 316.66M |
| October 28, 2026 | 328.29M |
| October 27, 2026 | 325.96M |
| October 26, 2026 | 267.04M |
| October 23, 2026 | 273.50M |
| October 22, 2026 | 351.55M |
| October 21, 2026 | 363.69M |
| October 20, 2026 | 369.38M |
| October 19, 2026 | 334.49M |
| October 16, 2026 | 317.95M |
| October 15, 2026 | 364.47M |
| October 14, 2026 | 348.96M |
| October 13, 2026 | 387.98M |
| October 12, 2026 | 432.95M |
| October 09, 2026 | 504.79M |
| October 08, 2026 | 493.94M |
| October 07, 2026 | 476.11M |
| October 06, 2026 | 527.02M |
| Date | Value |
|---|---|
| October 05, 2026 | 532.44M |
| October 02, 2026 | 564.75M |
| October 01, 2026 | 562.68M |
| September 30, 2026 | 600.67M |
| September 29, 2026 | 546.05M |
| September 28, 2026 | 538.30M |
| September 25, 2026 | 544.24M |
| September 24, 2026 | 571.37M |
| September 23, 2026 | 635.95M |
| September 22, 2026 | 683.74M |
| September 21, 2026 | 680.90M |
| September 18, 2026 | 712.16M |
| September 17, 2026 | 728.43M |
| September 16, 2026 | 705.44M |
| September 15, 2026 | 734.63M |
| September 14, 2026 | 830.73M |
| September 11, 2026 | 788.11M |
| September 10, 2026 | 828.40M |
| September 09, 2026 | 754.01M |
| September 08, 2026 | 833.57M |
| September 04, 2026 | 855.53M |
| September 03, 2026 | 828.40M |
| September 02, 2026 | 831.50M |
| September 01, 2026 | 712.41M |
| August 31, 2026 | 667.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cypherpunk Technologies, Inc. | 246.74M |
| Zymeworks, Inc. | 2.215B |
| Rhythm Pharmaceuticals, Inc. | 7.797B |
| Cue Biopharma, Inc. | 96.74M |
| Yarrow Bioscience, Inc. | -12.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.40M |
| Total Expenses (Quarterly) | 20.40M |
| EPS Diluted (Quarterly) | -0.7894 |
| Earnings Yield | -1.09K% |
| Normalized Earnings Yield | -490.91 |